Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...

The scarring of lungs is caused by some unknown origin. The exact mechanism of action of Pirfenidone (Pirfenex 200mg) is not known. Pirfenidone (Pirfenex 200mg) is thought to reduce the lung ...

Pirfenidone is currently approved for treating adults with idiopathic lung fibrosis, or scarring in the lungs that makes it hard to breathe. While the mechanism of action has not been fully ...

and pirfenidone (Esbriet), both of which can slow disease progression. Nerandomilast, which inhibits the enzyme phosphodiesterase 4B (PDE4B), is poised to offer a novel mechanism of action that ...